<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26918">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02141815</url>
  </required_header>
  <id_info>
    <org_study_id>S55578</org_study_id>
    <nct_id>NCT02141815</nct_id>
  </id_info>
  <brief_title>The Effect of Arabinoxylan-oligosaccharides (AXOS) on Intestinal Generation of Microbial Metabolites in Chronic Kidney Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease is associated with the accumulation of various metabolites, i.e.,
      uremic retention solutes. Evidence is mounting that the colonic microbiota contributes
      substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are
      among the most extensively studied gut microbial metabolites, and are associated with
      cardiovascular disease, overall mortality and chronic kidney disease progression. The most
      important regulator of colonic bacterial metabolism is nutrient availability and especially
      the ratio of available fermentable carbohydrate to nitrogen, which can be modified by intake
      of so-called prebiotics (non-digestible food ingredients). Arabinoxylan oligosaccharides
      (AXOS) are a recently developed group of prebiotics, and already demonstrated a decreasing
      effect on intestinal generation of p-cresol in healthy individuals. Whether prebiotics in
      general, and AXOS more specifically, can influence intestinal generation of microbial
      metabolites in predialysis patients has not been studied to date. An interventional study
      with AXOS will therefore be initiated to test the hypothesis that AXOS can decrease
      intestinal generation and serum concentrations of microbial metabolites in patients with CKD
      not yet on dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum levels of p-cresol and indole derivatives</measure>
    <time_frame>After 4 weeks of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion rates of p-cresol and indole derivatives</measure>
    <time_frame>After 4 weeks of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insuline resistance</measure>
    <time_frame>After 4 weeks of intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Insuline resistance, measured by HOMA index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Arabinoxylan-oligosaccharides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arabinoxylan-oligosaccharides 10g BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arabinoxylan-oligosaccharides</intervention_name>
    <arm_group_label>Arabinoxylan-oligosaccharides</arm_group_label>
    <other_name>AXOS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 85  years

          -  Chronic kidney disease stage 3b-4, i.e., with estimated glomerular filtration rate
             (CKD-epi) between 45 - 15 ml/min/m²  29

          -  Written informed consent

        Exclusion Criteria:

          -  History of organic gastro-intestinal disease (e.g., inflammatory bowel disease,
             malignancy)

          -  History of colonic surgery

          -  Recipient of a renal or other solid organ transplant

          -  Use of pre-/pro-/syn- or antibiotics in preceding 4 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Poesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Björn Meijers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruben Poesen, MD</last_name>
    <phone>+3216330010</phone>
    <email>ruben.poesen@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Poesen, MD</last_name>
      <phone>+3216330010</phone>
      <email>ruben.poesen@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Ruben Poesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Björn Meijers, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
